NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capital published a report that described Soleno’s only product, Vyka ...